Patent ID: 8236513
Filing Date: 2012-08-07
Classification: A61K,C07K,G01N

Abstract:
1. A method of determining immunoresistance to botulinum toxin therapy in an individual, the method comprising the steps of: a) combining a BoNT/A peptide with a test sample under conditions suitable for the selective binding of the BoNT/A peptide to an anti-BoNT antibody, the BoNT/A peptide having a length of at least six amino acids and at most 60 amino acids; wherein the BoNT/A peptide has a length of at least six amino acids and at most 60 amino acids and comprises amino acids 519-537 of SEQ ID NO: 1, a conservative BoNT/A amino acid sequence variant thereof, and an immunoreactive BoNT/A amino acid sequence fragment thereof; wherein the conservative BoNT/A amino acid sequence variant immunoreactive with the BoNT antibodies comprises 1-4 conservative amino acid substitutions to amino acids 519-537 of SEQ ID NO 1 wherein the immunoreactive BoNT/A amino acid sequence fragment immunoreactive with the BoNT antibodies comprises at least six consecutive amino acids of 519-537 of SEQ ID NO: 1 and b) determining the presence of an anti-BoNT antibody-BoNT/A peptide complex, the antibody-peptide complex formed by the selective binding of an anti-BoNT antibody and the BoNT/A peptide; where the presence of the anti-BoNT antibody-BoNT/A peptide complex is indicative of immunoresistance to a BoNT therapy.